vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and JOINT Corp (JYNT). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $15.2M, roughly 1.2× JOINT Corp). JOINT Corp runs the higher net margin — 6.5% vs -0.8%, a 7.4% gap on every dollar of revenue. On growth, JOINT Corp posted the faster year-over-year revenue change (3.1% vs -25.7%). JOINT Corp produced more free cash flow last quarter ($334.7K vs $-15.8M). Over the past eight quarters, CytomX Therapeutics, Inc.'s revenue compounded faster (-15.9% CAGR vs -28.6%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.
CTMX vs JYNT — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $15.2M |
| Net Profit | $-154.0K | $991.1K |
| Gross Margin | — | 81.4% |
| Operating Margin | -6.9% | 4.9% |
| Net Margin | -0.8% | 6.5% |
| Revenue YoY | -25.7% | 3.1% |
| Net Profit YoY | 97.6% | 5510.5% |
| EPS (diluted) | — | $0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $15.2M | ||
| Q3 25 | — | $13.4M | ||
| Q2 25 | $18.7M | $13.3M | ||
| Q1 25 | $50.9M | $13.1M | ||
| Q4 24 | $38.1M | $14.7M | ||
| Q3 24 | $33.4M | $30.2M | ||
| Q2 24 | $25.1M | $30.3M | ||
| Q1 24 | $41.5M | $29.7M |
| Q4 25 | — | $991.1K | ||
| Q3 25 | — | $855.0K | ||
| Q2 25 | $-154.0K | $93.4K | ||
| Q1 25 | $23.5M | $967.8K | ||
| Q4 24 | $18.9M | $17.7K | ||
| Q3 24 | $5.7M | $-3.2M | ||
| Q2 24 | $-6.5M | $-3.6M | ||
| Q1 24 | $13.8M | $947.0K |
| Q4 25 | — | 81.4% | ||
| Q3 25 | — | 80.1% | ||
| Q2 25 | — | 79.1% | ||
| Q1 25 | — | 77.3% | ||
| Q4 24 | — | 78.4% | ||
| Q3 24 | — | 90.7% | ||
| Q2 24 | — | 90.7% | ||
| Q1 24 | — | 90.9% |
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | -6.9% | -8.6% | ||
| Q1 25 | 44.4% | -5.2% | ||
| Q4 24 | 46.4% | 5.5% | ||
| Q3 24 | 12.3% | -1.6% | ||
| Q2 24 | -33.7% | -5.9% | ||
| Q1 24 | 28.1% | -1.4% |
| Q4 25 | — | 6.5% | ||
| Q3 25 | — | 6.4% | ||
| Q2 25 | -0.8% | 0.7% | ||
| Q1 25 | 46.2% | 7.4% | ||
| Q4 24 | 49.6% | 0.1% | ||
| Q3 24 | 17.2% | -10.5% | ||
| Q2 24 | -26.0% | -11.9% | ||
| Q1 24 | 33.3% | 3.2% |
| Q4 25 | — | $0.06 | ||
| Q3 25 | — | $0.06 | ||
| Q2 25 | — | $0.01 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | — | $0.01 | ||
| Q3 24 | — | $-0.21 | ||
| Q2 24 | — | $-0.24 | ||
| Q1 24 | — | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $23.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $15.1M |
| Total Assets | $175.1M | $61.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $23.6M | ||
| Q3 25 | — | $29.7M | ||
| Q2 25 | $49.0M | $29.8M | ||
| Q1 25 | $47.6M | $21.9M | ||
| Q4 24 | $38.1M | $25.1M | ||
| Q3 24 | $40.6M | $20.7M | ||
| Q2 24 | $43.2M | $17.5M | ||
| Q1 24 | $36.2M | $18.7M |
| Q4 25 | — | $15.1M | ||
| Q3 25 | — | $22.7M | ||
| Q2 25 | $119.9M | $23.2M | ||
| Q1 25 | $25.0M | $22.8M | ||
| Q4 24 | $-456.0K | $20.7M | ||
| Q3 24 | $-23.5M | $20.5M | ||
| Q2 24 | $-31.2M | $23.2M | ||
| Q1 24 | $-31.7M | $26.2M |
| Q4 25 | — | $61.0M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | $175.1M | $73.2M | ||
| Q1 25 | $98.5M | $80.1M | ||
| Q4 24 | $120.5M | $83.2M | ||
| Q3 24 | $139.0M | $79.6M | ||
| Q2 24 | $159.2M | $82.4M | ||
| Q1 24 | $184.7M | $85.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $1.8M |
| Free Cash FlowOCF − Capex | $-15.8M | $334.7K |
| FCF MarginFCF / Revenue | -84.6% | 2.2% |
| Capex IntensityCapex / Revenue | 0.1% | 9.9% |
| Cash ConversionOCF / Net Profit | — | 1.86× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-1.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.8M | ||
| Q3 25 | — | $1.8M | ||
| Q2 25 | $-15.8M | $868.6K | ||
| Q1 25 | $-21.0M | $-3.7M | ||
| Q4 24 | $-19.9M | $9.4M | ||
| Q3 24 | $-20.7M | $3.4M | ||
| Q2 24 | $-19.5M | $-973.5K | ||
| Q1 24 | $-26.0M | $2.8M |
| Q4 25 | — | $334.7K | ||
| Q3 25 | — | $1.5M | ||
| Q2 25 | $-15.8M | $363.6K | ||
| Q1 25 | $-21.2M | $-4.0M | ||
| Q4 24 | $-20.0M | $8.2M | ||
| Q3 24 | $-20.7M | $3.2M | ||
| Q2 24 | $-19.6M | $-1.2M | ||
| Q1 24 | $-26.2M | $2.4M |
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 10.9% | ||
| Q2 25 | -84.6% | 2.7% | ||
| Q1 25 | -41.6% | -30.8% | ||
| Q4 24 | -52.5% | 55.9% | ||
| Q3 24 | -62.1% | 10.6% | ||
| Q2 24 | -78.2% | -4.1% | ||
| Q1 24 | -63.1% | 8.1% |
| Q4 25 | — | 9.9% | ||
| Q3 25 | — | 2.4% | ||
| Q2 25 | 0.1% | 3.8% | ||
| Q1 25 | 0.2% | 2.5% | ||
| Q4 24 | 0.2% | 8.1% | ||
| Q3 24 | 0.1% | 0.8% | ||
| Q2 24 | 0.4% | 0.9% | ||
| Q1 24 | 0.3% | 1.3% |
| Q4 25 | — | 1.86× | ||
| Q3 25 | — | 2.07× | ||
| Q2 25 | — | 9.30× | ||
| Q1 25 | -0.89× | -3.82× | ||
| Q4 24 | -1.05× | 532.98× | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | 2.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
JYNT
| Transferred At Point In Time | $12.8M | 84% |
| Transferred Over Time | $2.4M | 16% |
